TRIB3 and breast carcinoma: Yu et al. showed that the C-terminal structural domain of TRIB3 in breast cancer interacts with AKT1 to interfere with FOXO1-AKT1 interactions and inhibit FOXO1 phosphorylation and ubiquitination, which further promotes the expression of the transcription factor SOX2 and confers stemness on BC cells to promote their proliferation and migration (Yu et al., 2019).